GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates
By Shannon Mullican, Xiefan Lin-Schmidt, C. Chin, J. Chavez, J. Furman, A. Armstrong, S. C. Beck, V. South, T. Dinh, T. Cash-Mason and 5 more. Nature Medicine, 2017
651 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Physiology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/ff29c4256639b979e1e91ff0b4d768ef989216c5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
Citations in the corpus
- Metabolically Healthy Obesity (2020, background): “Most of these drugs are in preclinical development or at early stages of clinical development and include centrally acting agents (setmelanotide, neuropeptide Y antagonists, peptide YY, and cannabinoid type-1 receptor blockers) (117–120), amylin mimetics (davalintide, dual amylin, and calcitonin rec”